Invivyd Posts $33.5M Q3 Loss, $15.4M Revenue as Cash Concerns Linger
IVVD is trading near its 52-week low of $0.528 (8.6% above the low).
Summary
Invivyd reported a Q3 net loss of $33.468 million on revenue of $15.449 million, with EPS of -$0.10. The loss is narrower than the $44.4 million Q2 loss disclosed in the August 10-Q, but the company still carries going-concern doubt, a Nasdaq delisting notice, and the loss of its only authorized product's EUA. Revenue of $15.4 million is the key line to weigh against that burn. This follows the September 29 positive Phase 3 LIBERTY data for VYD2311, which remains the main lever for the story.
At the time of this announcement, IVVD was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.6M. The 52-week trading range was $0.53 to $3.07. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.